News

Filter

Current filters:

Gentiumdefibrotide

Italy’s Gentium accepts $1 billion takeover offer from Jazz Pharma

20-12-2013

Ireland-headquartered drugmaker Jazz Pharmaceuticals has entered into a definitive agreement to acquire…

defibrotideDefitelioGentiumItalyJazz PharmaceuticalsMergers & AcquisitionsNephrology and HepatologyPharmaceuticalRare diseases

Positive EU regulatory news for Alexza and Ferrer, but not Gentium

22-02-2013

USA-based Alexza Pharmaceuticals (Nasdaq: ALXA) and Spanish partner Grupo Ferrer Internacional have received…

AdasuveAlexza PharmaceuticalBiotechnologydefibrotideEuropeFerrer InternacionalGentiumNephrology and HepatologyNeurologicalPharmaceuticalRegulation

PharmaSwiss to distribute Gentium's defibrotide in CEE and other countries

03-05-2012

Italian drugmaker Gentium SpA (Nasdaq: GENT) has appointed PharmaSwiss, a division of Canada's Valeant…

defibrotideEuropeGentiumLicensingNephrology and HepatologyPharmaceuticalPharmaSwissValeant Pharmaceuticals

Gentium withdraws US NDA for defibrotide

19-08-2011

Italian drug developer Gentium SpA (Nasdaq: GENT) saw its shares price plunge 29% to $6.22 on the Nasdaq…

Cardio-vasculardefibrotideGentiumNorth AmericaPharmaceuticalRegulationSigma Tau

Back to top